June 22, 2016
(MIT Technology Review) – The first clinical trial for a Zika virus vaccine just received a green light from the FDA. Inovio Pharmaceuticals and GeneOne Life Science announced on Monday that their vaccine, called GLS-5700, will undergo phase I clinical testing for safety in 40 healthy volunteers within a few weeks. Inovio’s effort has plenty of company—the National Institutes of Health, the French pharmaceutical giant Sanofi, and the India-based Bharat Biotech all have Zika vaccines in the works.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.